Prior to 2007, exosomes were largely considered to be tiny “trash sacs” thrown out of living cells. Around 2007, it as discovered that exosomes carry RNAs and miRNAs, along with other molecules to regulate the expression of genes between cells. This discovery paved the way for the scientists to search for improved techniques for the exploitation of exosomes in treating diseases. [Read more…]
Taking EV characterization to the next level with ONI’s Nanoimager
Extracellular vesicles (EVs) are known for their role in facilitating wide range of intercellular communication such as regulation of the immune response and stem cells differentiation.
What is an extra-cellular vesicle?
EVs are membrane-enclosed particles ranging in size from 30nm to 300nm and their characteristic depend on the cell type releasing them. Often they will carry cargo of active molecules like RNA, DNA, proteins, metabolites and lipids. Moreover, EVs can be found in most biological fluids with the ability to cross biological barriers, and in the case of pathological conditions, the composition of the cargo will be distinctive to the disease. Altogether, these features have led to intense research into the potential role of EVs for diagnostics, biomarkers and as vehicles for drug delivery. [Read more…]
Top 4 Most Richly Funded Exosome Startups
In recent years, exosome start-up companies have been the recipients of hundreds of millions of dollars in investor funding. Clearly, investors are feeling favorable toward companies developing exosome products and there is a growing belief that the industry is poised for growth. [Read more…]
NurExone Biologic Achieves Key Milestone in Support of Robust Exosome Manufacturing Process
-
Company demonstrates reliable production from multiple biological sources
-
These manufacturing advancements provide NurExone flexibility in optimizing its exosome production method, ensuring consistency while maintaining efficiency
TORONTO and HAIFA, Israel, Aug. 15, 2024 — NurExone Biologic Inc. (TSXV: NRX), (OTCQB: NRXBF), announces significant advancements in their manufacturing process of exosomes. Exosomes, which are naturally released by cells, hold immense promise for regenerative medicine and they are at the heart of the Company’s innovative ExoPTEN product, which is being developed for the treatment of acute spinal cord injury and glaucoma. [Read more…]
Aegle Therapeutics Corp. Announces First Patient Dosed in Phase 1/2a Trial of AGLE-102™ in Patients with Dystrophic Epidermolysis Bullosa (“DEB”)
AGLE-102 is a novel extracellular vesicle therapy being developed for the treatment of rare and immuno-dermatological disorders.
WOBURN, Mass., Aug. 14, 2024 — Aegle Therapeutics Corp., a clinical-stage biopharmaceutical company developing novel extracellular vesicle (“EV”) therapies to address immune and inflammatory-based dermatological disorders, today announced that the first patient has been dosed in a Phase 1/2a clinical study evaluating AGLE-102™ for the treatment of the rare pediatric skin blistering disease DEB. [Read more…]
- « Previous Page
- 1
- …
- 7
- 8
- 9
- 10
- 11
- …
- 27
- Next Page »